preloader

Benefits of ovarian function suppression confirmed in young breast cancer women

Intro text: 

- Wednesday 13 December 2017 -
 

Updated results of the SOFT and TEXT trials

The updated results of the international, randomised phase III SOFT and TEXT trials were presented last week at the San Antonio Breast Cancer Symposium. They confirmed the benefit of ovarian suppression in reducing the risk of cancer recurrence for selected premenopausal women with hormone-sensitive early breast cancer who receive a post-operative endocrine treatment.

Read the press release

Based on a median follow-up of 9 years, the combined analysis of SOFT and TEXT confirmed that exemestane, compared to tamoxifen, significantly improved patient disease outcome when used in combination with ovarian function suppression. Clear clinical benefits were observed, especially in patients with a high risk of cancer recurrence who received adjuvant chemotherapy.

Researchers also presented updates of the SOFT trial after 8 years follow-up, which showed that adding ovarian suppression to tamoxifen significantly decreased the relative risk of disease-free survival events by 24% compared to tamoxifen alone. The clinical benefits were most pronounced in women younger than 35 with a relative risk reduction of 44%.

These results support the trials’s first findings presented after 5 years treatment and published in the New England Journal of Medicine in 2014.

While the follow-up of the 5,738 participating patients continues, SOFT and TEXT together have already provided practice-changing results, giving doctors a new post-operative treatment option for young women with hormone-sensitive early breast cancer who may have a higher risk of cancer recurrence after surgery.

Both trials are led by the International Breast Cancer Study Group (IBCSG), in partnership with the Breast International Group (BIG) and the North American Breast Cancer Group (NABCG), and supported by IBCSG, Pfizer, Ipsen, the U.S. National Cancer Institute (NCI), and the Breast Cancer Research Foundation (BCRF).